Sacubitril/Valsartan Treatment in Heart Failure Increases The Left Ventricular Ejection Fraction: A Bayesian Analysis

Yıl 2022, Cilt: 25 Sayı: 3, 250 - 256, 01.12.2022

Oğuzhan Birdal Mehmet Saygı Pınar Demir Gündoğmuş Emrah Aksakal Flora Özkalaycı

Öz

Introduction: Heart failure is an important leading cause of mortality and morbidity despite optimal medical treatment and device therapy. Sacubitril/valsartan, a first-generation drug, was approved to use heart failure treatment recently. There are limited studies on the relationship between sacubitril/valsartan and left ventricular contraction. In our study, we aimed to evaluate the changes in left ventricular ejection fraction (LVEF) after sacubitril/valsartan treatment.

Patients and Methods: Fifty-two patients with heart failure and reduced ejection fraction (HFrEF) were enrolled in this study. The baseline demographic, clinical, and echocardiographic characteristics of 52 patients were compared using the Bayesian method.

Results: Fifty-two patients with heart failure and reduced ejection fraction (HFrEF) were included in the final analysis (66.2 ± 9.3 years, 69.2% male). Sacubitril/valsartan initial dose was low in 44.2% of patients, and intermediate in 55.8%. In the low initial dose population, the increase in absolute LVEF was 3.87 (95% HDI 1.53-6.20) and in the intermediate initial dose population, the increase in absolute LVEF was 5.89 (95% HDI 4.18-7.61). In the female population, the increase in absolute LVEF was 5.56 (95% HDI 3.49-7.63) and in the male population 4.75 (95% HDI 2.91-6.58) respectively.

Conclusion: In this study, we demonstrated that sacubitril/valsartan is associated with increased LVEF regardless of baseline clinical characteristics.

Anahtar Kelimeler

ARNI, bayesian, ejection fraction

Kaynakça

• 1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14(8):803-69.
• 2. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation 2010;121(7):948-54. [Crossref]
• 3. Burnett H, Earley A, Voors AA, Senni M, McMurray JJ, Deschaseaux C, et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: A network meta-analysis. Circ Heart Fail 2017;10(1):003529. [Crossref]
• 4. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371(11):993-1004. [Crossref]
• 5. Elshafey WEH, Al Khoufi EA, Elmelegy EK. Effects of sacubitril/valsartan treatment on left ventricular myocardial torsion mechanics in patients with heart failure reduced ejection fraction 2D speckle tracking echocardiography. J Cardiovasc Echogr 2021;31(2):59-67. [Crossref]
• 6. Pericas P, Mas-Llado C, Ramis-Barcelo MF, Valadron I, Noris Mora M, Pasamar Marquez L, et al. Impact of sacubitril-valsartan treatment on diastolic function in patients with heart failure and reduced ejection fraction. High Blood Press Cardiovasc Prev 2021;28(2):167-75. [Crossref]
• 7. Lee S, Oh J, Kim H, Ha J, Chun KH, Lee CJ, et al. Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease. ESC Heart Fail 2020;7(3):1125-29. [Crossref]
• 8. Ekici B, Yaman M, Kucuk M, Dereli S, Yenercag M, Yigit Z, et al. Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR). Turk Kardiyol Dern Ars 2021;49(5):357-67. [Crossref]
• 9. Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby DE. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension 2004;44(6):913-8. [Crossref]
• 10. Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T. Neutral endopeptidase inhibition: Augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci (Lond) 1996;91(3):283-91. [Crossref]
• 11. Wilkinson IB, McEniery CM, Bongaerts KH, MacCallum H, Webb DJ, Cockcroft JR. Adrenomedullin (ADM) in the human forearm vascular bed: Effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP). Br J Clin Pharmacol 2001;52(2):159-64. [Crossref]
• 12. Schmieder RE, Wagner F, Mayr M, Delles C, Ott C, Keicher C, et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: The results of a randomized, double-blind, active-controlled study. Eur Heart J 2017;38(44):3308-17. [Crossref]
• 13. Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: A post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 2017;5(5):333-40. [Crossref]
• 14. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., Colvin MM, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: An update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Circulation 2016;134(13):282-93. [Crossref]
• 15. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37(27):2129-200. [Crossref]
• 16. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure. J Am Coll Cardiol 2000;35(5):1245-55. [Crossref]
• 17. King JB, Shah RU, Bress AP, Nelson RE, Bellows BK. Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC Heart Fail 2016;4(5):392-402. [Crossref]
• 18. Castrichini M, Manca P, Nuzzi V, Barbati G, De Luca A, Korcova R, et al. Sacubitril/valsartan induces global cardiac reverse remodeling in long-lasting heart failure with reduced ejection fraction: Standard and advanced echocardiographic evidences. J Clin Med 2020;9(4):906. [Crossref]